Literature DB >> 17526939

Observation of hypertension in children with 21-hydroxylase deficiency: a preliminary report.

Todd D Nebesio1, Erica A Eugster.   

Abstract

The most common cause of congenital adrenal hyperplasia is 21-hydroxylase deficiency (21OHD). The prevalence of hypertension (HTN) in children with 21OHD is unknown, and HTN has not been reported to be a component of this disorder. As children with 21OHD are at risk of developing obesity, we hypothesized that an elevated body mass index (BMI) would be a predictive factor in the development of HTN. A retrospective chart review of children with 21OHD seen in our pediatric endocrine clinics for the past 21 yr was performed. Ninety-one children with 21OHD were identified (54% female). Of these children, six (6.6%) had HTN, and five (5.6%) had essential HTN, which was defined as HTN of unknown etiology. Elevated body mass index was not a determining factor in the development of HTN. Children with 21OHD do appear to have a higher prevalence of HTN when compared to historical reports of pediatric populations. The coexistence of HTN with a salt-wasting state and mineralocorticoid deficiency in some children with 21OHD is paradoxical and of unclear etiology.

Entities:  

Mesh:

Year:  2006        PMID: 17526939     DOI: 10.1007/s12020-006-0005-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  15 in total

Review 1.  Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

2.  Overweight, ethnicity, and the prevalence of hypertension in school-aged children.

Authors:  Jonathan M Sorof; Dejian Lai; Jennifer Turner; Tim Poffenbarger; Ronald J Portman
Journal:  Pediatrics       Date:  2004-03       Impact factor: 7.124

3.  Blood pressure in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Wolfgang Hoepffner; Alexander Herrmann; Helmut Willgerodt; Eberhard Keller
Journal:  J Pediatr Endocrinol Metab       Date:  2006-05       Impact factor: 1.634

4.  Prevalence of hypertension in junior high school-aged children: effect of new recommendations in the 1996 Updated Task Force Report.

Authors:  H E Adrogué; A R Sinaiko
Journal:  Am J Hypertens       Date:  2001-05       Impact factor: 2.689

Review 5.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  P C White; P W Speiser
Journal:  Endocr Rev       Date:  2000-06       Impact factor: 19.871

Review 6.  Renin inhibition: what are the therapeutic opportunities?

Authors:  Naomi D L Fisher; Norman K Hollenberg
Journal:  J Am Soc Nephrol       Date:  2005-02-09       Impact factor: 10.121

7.  Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Authors: 
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

8.  The relationship of body mass index and blood pressure in primary care pediatric patients.

Authors:  Bonita Falkner; Samuel S Gidding; Gabriela Ramirez-Garnica; Stacey Armatti Wiltrout; David West; Elizabeth B Rappaport
Journal:  J Pediatr       Date:  2006-02       Impact factor: 4.406

9.  Obesity in 21-hydroxylase deficient patients.

Authors:  R E Cornean; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

10.  Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.

Authors:  Edna F Roche; Evangelia Charmandari; Mehul T Dattani; Peter C Hindmarsh
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

View more
  12 in total

1.  Early hypertension and prolonged mineralocorticoid therapy discontinuation in a child with salt-wasting 21-hydroxylase deficiency.

Authors:  M Wasniewska; M Valenzise; T Aversa; S Mirabelli; F De Luca; F L De Luca; F Lombardo
Journal:  J Endocrinol Invest       Date:  2011-02       Impact factor: 4.256

2.  Carotid intima media thickness and other cardiovascular risk factors in children with congenital adrenal hyperplasia.

Authors:  N H Amr; A Y Ahmed; Y A Ibrahim
Journal:  J Endocrinol Invest       Date:  2014-08-12       Impact factor: 4.256

Review 3.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

Review 4.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

5.  Management of the adult with congenital adrenal hyperplasia.

Authors:  Richard J Auchus
Journal:  Int J Pediatr Endocrinol       Date:  2010-05-30

6.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

Review 7.  Cardiovascular disease risk in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mimi S Kim; Deborah P Merke
Journal:  Semin Reprod Med       Date:  2009-06-15       Impact factor: 1.303

Review 8.  Approach to the patient: the adult with congenital adrenal hyperplasia.

Authors:  Richard J Auchus; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2013-07       Impact factor: 5.958

9.  Clinical Patterns and Linear Growth in Children with Congenital Adrenal Hyperplasia, an 11-Year Experience.

Authors:  Adnan Al Shaikh; Yasser AlGhanmi; Saniah Awidah; Abdullah Bahha; Mohamed E Ahmed; Ashraf T Soliman
Journal:  Indian J Endocrinol Metab       Date:  2019 May-Jun

10.  Metabolic profile and cardiovascular risk factors in adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mouna Feki Mnif; Mahdi Kamoun; Fatma Mnif; Nadia Charfi; Basma Ben Naceur; Nozha Kallel; Nabila Rekik; Zainab Mnif; Mohamed Habib Sfar; Mohamed Tahar Sfar; Mongia Hachicha; Mohamed Abid
Journal:  Indian J Endocrinol Metab       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.